## ACHC: Acadia Healthcare Company, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -12.6% below STRENGTH zone (3.0-6.0%); PEG 1.32 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-14.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($11.70)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Acadia Healthcare Company, Inc. (ACHC) and Encourages Stockholders to Learn More About the Investigation**
- Source: WJBF | 20251207T162139 | Neutral | Relevance: 98%
-  Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims against Acadia Healthcare Company, Inc. (ACHC) after the company disclosed higher anticipated patient-related litigation costs and significantly reduced its full-year 2025 Adjusted EBITDA guidance. The firm is encouraging investors who purchased Acadia securities to learn more about the investigation as the company's stock price dropped following this news. The investigation aims to determine if there were any misrepresentations or omissions that may have led to investor losses.

**2. Bronstein, Gewirtz & Grossman, LLC Encourages Acadia Healthcare Company, Inc. (ACHC) Investors to Inquire about Securities Investigation**
- Source: FOX 2 | 20251207T162139 | Neutral | Relevance: 98%
-  Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased Acadia Healthcare Company, Inc. (ACHC) securities prior to February 28, 2020. The investigation aims to determine if Acadia Healthcare and its officers/directors engaged in corporate wrongdoing. Investors are encouraged to contact the firm for more information and to assist in the investigation.

**3. Acadia Healthcare (NASDAQ:ACHC) Stock Price Down 7.3% - Here's What Happened**
- Source: MarketBeat | 20251208T190932 | Neutral | Relevance: 97%
-  Acadia Healthcare's stock price dropped 7.3% on Monday on unusually light trading volume, closing at $14.3460. This decline follows several analyst downgrades, including Leerink Partnrs to "hold" and Mizuho cutting its price target. Although the company slightly beat Q3 EPS estimates, it missed revenue expectations and provided FY2025 guidance of 2.350â€“2.450 EPS.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 11)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Barclays | $14 | $17 | -18% |
| 2025-12-03 | RBC Capital | $19 | $22 | -14% |
| 2025-12-03 | Cantor Fitzgera | $17 | $22 | -23% |
| 2025-12-03 | Keybanc | $25 | $30 | -17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Barclays | main | Equal-Weight |
| 2025-12-03 | RBC Capital | main | Outperform |
| 2025-12-03 | Cantor Fitzgera | main | Neutral |
| 2025-12-03 | Keybanc | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.02M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 0 |

**Top Holders:**
- Blackrock Inc.: 11.9% (+20.4%)
- Vanguard Group Inc: 10.2% (+7.8%)
- Wellington Managemen: 10.2% (+11.8%)
- FMR, LLC: 6.6% (+2.2%)
- Khrom Capital Manage: 5.5% (+103.0%)

### Key Risks

1. High short interest (15.0%, 5.0 days to cover): squeeze risk or crowded bearish bet.
2. Long-term trend broken: trading 40.3% below SMA200.
3. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.32 suggests fair value with growth premium. Analyst sentiment negative (11 target cuts vs 0 raises). Institutional flow bullish (9 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.3B |
| Beta | 0.90 |
| 52W Range | $12.63 - $47.08 |
| Short Interest | 15.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.32 |
| Forward P/E | 7.1 |
| Current P/E | 6.7 |
| YoY Growth | -5.3% |
| EPS Direction | FALLING |

### Technicals

MRS_10 deteriorating from 1.5% to -12.6% (-14.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 15.6pp (needs >3.0% for momentum thesis). Underperforming sector by 9.2pp, stock-specific weakness. Below SMA200 (0.60x), long-term trend not supportive.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -12.58% (CS: 0) | Weak |
| RSI_14 | 30.1 | Neutral |
| MACD Histogram | 0.09 | Bullish |
| vs SMA20 | 0.878x | Below |
| vs SMA50 | 0.679x | Below |
| vs SMA200 | 0.597x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $14.00
- **Stop Loss:** $11.70 (16.4% risk)
- **Target:** $16.30 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 217
- **Position Value:** $3,038.00
- **Portfolio %:** 3.04%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-26 (Est: $0.13)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.66 | $0.72 | +9.2% |
| 2025Q2 | $0.71 | $0.83 | +17.4% |
| 2025Q1 | $0.36 | $0.40 | +12.0% |
| 2024Q4 | $0.71 | $0.64 | -10.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*